University of California San Francisco

Javid Moslehi, MD
Javid Moslehi, MD

Professor, Medicine
School of Medicine

Address

555 Mission Bay Blvd South, #001
San Francisco, CA 94158
United States

Email: [email protected]
Phone: 415-502-3119

Education

Institution Degree Dept or School End Date
Dana-Farber Cancer Institute Post-Doctoral Fellowship, Oncology 05/2014
Brigham and Women's Hospital Fellowship, Cardiology 06/2007
Johns Hopkins Hospital Residency, Internal Medicine 06/2004
University of Connecticut MD Medicine 06/2001
Johns Hopkins University BA Biology 06/1996

Awards & Honors

Award Conferred By Date
Elected Member Association of American Physicians (AAP) 2024
Inaugural Holder of the William Grossman Distinguished Professorship in Cardiology UCSF 2021
Elected Member American Society of Clinical Investigation (ASCI) 2020
Alumni Achievement Award Stanley J. Sarnoff Cardiovascular Research Foundation 2016
Biomedical Science Impact Award Vanderbilt University 2016
Thomas Smith Award in Heart Failure Research Brigham and Women's Hospital, Harvard Medical School 2009

Grants and Funding

  • Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis | NIH | 2021-05-01 - 2026-04-30 | Role: Principal Investigator
  • Long-Term Cardiovascular Sequelae of Cancer Immunotherapies | NIH | 2021-05-01 - 2026-04-30 | Role: Principal Investigator
  • Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension | NIH | 2019-08-01 - 2024-05-31 | Role: Principal Investigator
  • Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension | NIH | 2018-09-15 - 2019-08-31 | Role: Principal Investigator
  • A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy | NIH | 2009-09-30 - 2014-06-30 | Role: Principal Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 281
  1. Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis.
    Fankhauser RG, Johnson DB, Moslehi JJ, Balko JM| | PubMed
  2. Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction.
    Chen YC, Dolladille C, Rao A, Palaskas NL, Deswal A, Lehmann L, Cautela J, Courand PY, Hayek S, Zhu H, Cheng RK, Alexandre J, Baldassarre LA, Roubille F, Laufer-Perl M, Asnani A, Ederhy S, Tamura Y, Francis S, Gaughan EM, Johnson DB, Flint DL, Rainer PP, Bailly G, Ewer SM, Aras MA, Arangalage D, Cariou E, Florido R, Peretto G, Itzhaki Ben Zadok O, Akhter N, Narezkina A, Levenson JE, Liu Y, Crusz SM, Issa N, Piriou N, Leong D, Sandhu S, Turker I, Moliner P, Obeid M, Heinzerling L, Chang WT, Stewart A, Venkatesh V, Du Z, Yadavalli A, Kim D, Chandra A, Zhang KW, Power JR, Moslehi J, Salem JE, Zaha VG, International ICI Myocarditis Registry| | PubMed
  3. Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report.
    Wadden E, Lai C, Grivas P, Bhatia S, Portuguese AJ, Salem JE, Moslehi JJ, Cheng RK| | PubMed
  4. Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.
    Bonaca MP, Lang NN, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M, Strnadova C, Klaar S, Dent S, Janicijevic TK, Herrmann J, Barac A, de Boer RA, Deswal A, Schou M, Neilan TG, van der Meer P, Moslehi J, Kondapalli L, Ky B, Fernandez TL, Cornell RF, Flaig TW, Hsia J, Sharon E, de Azambuja E, Seltzer J, Januzzi JL, Petrie MC| | PubMed
  5. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.
    Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O'Brien S, Garcia JS, Korde N, Moslehi J, Wey M, Cheung P, Sharma S, Olabode D, Chen H, Ali Syed F, Liu M, Saeh J, Andrade-Campos M, Kadia TM, Blachly JS| | PubMed
  6. Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation.
    Moslehi JJ| | PubMed
  7. Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.
    Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, Ciardiello F, Pane F, Au L, Emmerich M, Plummer C, Gulati G, Ramalingam S, Cardinale D, Brezden-Masley C, Iakobishvili Z, Thavendiranathan P, Santoro C, Bergler-Klein J, Keramida K, de Boer RA, Maack C, Lutgens E, Rassaf T, Fradley MG, Moslehi J, Yang EH, De Keulenaer G, Ameri P, Bax J, Neilan TG, Herrmann J, Mbakwem AC, Mirabel M, Skouri H, Hirsch E, Cohen-Solal A, Sverdlov AL, van der Meer P, Asteggiano R, Barac A, Ky B, Lenihan D, Dent S, Seferovic P, Coats AJS, Metra M, Rosano G, Suter T, Lopez-Fernandez T, Lyon AR| | PubMed
  8. Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and Myositis.
    Fankhauser RG, Johnson DB, Moslehi JJ, Balko JM| | PubMed
  9. Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository.
    Shannon ML, Heimlich JB, Olson S, Debevec A, Copeland Z, Kishtagari A, Vlasschaert C, Snider C, Silver AJ, Brown D, Spaulding T, Bhatta M, Pugh K, Stockton SS, Ulloa J, Xu Y, Baljevic M, Moslehi J, Jahangir E, Ferrell PB, Slosky D, Bick AG, Savona MR| | PubMed
  10. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.
    Munir AZ, Gutierrez A, Qin J, Lichtman AH, Moslehi JJ| | PubMed
281
View all 281 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 281
  1. Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis.
    Fankhauser RG, Johnson DB, Moslehi JJ, Balko JM| | PubMed
  2. Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction.
    Chen YC, Dolladille C, Rao A, Palaskas NL, Deswal A, Lehmann L, Cautela J, Courand PY, Hayek S, Zhu H, Cheng RK, Alexandre J, Baldassarre LA, Roubille F, Laufer-Perl M, Asnani A, Ederhy S, Tamura Y, Francis S, Gaughan EM, Johnson DB, Flint DL, Rainer PP, Bailly G, Ewer SM, Aras MA, Arangalage D, Cariou E, Florido R, Peretto G, Itzhaki Ben Zadok O, Akhter N, Narezkina A, Levenson JE, Liu Y, Crusz SM, Issa N, Piriou N, Leong D, Sandhu S, Turker I, Moliner P, Obeid M, Heinzerling L, Chang WT, Stewart A, Venkatesh V, Du Z, Yadavalli A, Kim D, Chandra A, Zhang KW, Power JR, Moslehi J, Salem JE, Zaha VG, International ICI Myocarditis Registry| | PubMed
  3. Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report.
    Wadden E, Lai C, Grivas P, Bhatia S, Portuguese AJ, Salem JE, Moslehi JJ, Cheng RK| | PubMed
  4. Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.
    Bonaca MP, Lang NN, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M, Strnadova C, Klaar S, Dent S, Janicijevic TK, Herrmann J, Barac A, de Boer RA, Deswal A, Schou M, Neilan TG, van der Meer P, Moslehi J, Kondapalli L, Ky B, Fernandez TL, Cornell RF, Flaig TW, Hsia J, Sharon E, de Azambuja E, Seltzer J, Januzzi JL, Petrie MC| | PubMed
  5. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.
    Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O'Brien S, Garcia JS, Korde N, Moslehi J, Wey M, Cheung P, Sharma S, Olabode D, Chen H, Ali Syed F, Liu M, Saeh J, Andrade-Campos M, Kadia TM, Blachly JS| | PubMed
  6. Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation.
    Moslehi JJ| | PubMed
  7. Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.
    Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, Ciardiello F, Pane F, Au L, Emmerich M, Plummer C, Gulati G, Ramalingam S, Cardinale D, Brezden-Masley C, Iakobishvili Z, Thavendiranathan P, Santoro C, Bergler-Klein J, Keramida K, de Boer RA, Maack C, Lutgens E, Rassaf T, Fradley MG, Moslehi J, Yang EH, De Keulenaer G, Ameri P, Bax J, Neilan TG, Herrmann J, Mbakwem AC, Mirabel M, Skouri H, Hirsch E, Cohen-Solal A, Sverdlov AL, van der Meer P, Asteggiano R, Barac A, Ky B, Lenihan D, Dent S, Seferovic P, Coats AJS, Metra M, Rosano G, Suter T, Lopez-Fernandez T, Lyon AR| | PubMed
  8. Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and Myositis.
    Fankhauser RG, Johnson DB, Moslehi JJ, Balko JM| | PubMed
  9. Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository.
    Shannon ML, Heimlich JB, Olson S, Debevec A, Copeland Z, Kishtagari A, Vlasschaert C, Snider C, Silver AJ, Brown D, Spaulding T, Bhatta M, Pugh K, Stockton SS, Ulloa J, Xu Y, Baljevic M, Moslehi J, Jahangir E, Ferrell PB, Slosky D, Bick AG, Savona MR| | PubMed
  10. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.
    Munir AZ, Gutierrez A, Qin J, Lichtman AH, Moslehi JJ| | PubMed
  11. Autoimmune Myocarditis, Old Dogs and New Tricks.
    Won T, Song EJ, Kalinoski HM, Moslehi JJ, Ciháková D| | PubMed
  12. Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity.
    Power JR, Dolladille C, Ozbay B, Procureur AM, Ederhy S, Palaskas NL, Lehmann LH, Cautela J, Courand PY, Hayek SS, Zhu H, Zaha VG, Cheng RK, Alexandre J, Roubille F, Baldassarre LA, Chen YC, Baik AH, Laufer-Perl M, Tamura Y, Asnani A, Francis S, Gaughan EM, Rainer PP, Bailly G, Flint D, Arangalage D, Cariou E, Florido R, Narezkina A, Liu Y, Sandhu S, Leong D, Issa N, Piriou N, Heinzerling L, Peretto G, Crusz SM, Akhter N, Levenson JE, Turker I, Eslami A, Fenioux C, Moliner P, Obeid M, Chan WT, Ewer SM, Kassaian SE, International ICI-Myocarditis Registry, Johnson DB, Nohria A, Zadok OIB, Moslehi JJ, Salem JE| | PubMed
  13. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ, Furman RR, Tam CS, Salem JE, Flowers CR, Cohen A, Zhang M, Zhang J, Chen L, Ma H, Brown JR| | PubMed
  14. PD-1-PD-L1 immunomodulatory pathway regulates cardiac regeneration.
    Qin J, Huang GN, Moslehi J| | PubMed
  15. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective.
    Gougis P, Jochum F, Abbar B, Dumas E, Bihan K, Lebrun-Vignes B, Moslehi J, Spano JP, Laas E, Hotton J, Reyal F, Hamy AS, Salem JE| | PubMed
  16. Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
    Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, International ICI-Myocarditis Registry, Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE| | PubMed
  17. B-Cell Immune Checkpoints Come of Age in Cardio-oncology.
    Gutierrez A, Moslehi JJ| | PubMed
  18. Ponatinib-Induced Cardiomyocyte Toxicity: Dark Side of the Integrated Stress Response.
    Liang FG, Moslehi J, Kitsis RN| | PubMed
  19. Genetic Interleukin-6 Receptor Variant Is Not Associated With Rejection and Mortality After Heart Transplantation.
    Amancherla K, Schlendorf KH, Vlasschaert C, Lowery BD, Wells QS, See SB, Zorn E, Colombo PC, Reilly MP, Lindenfeld J, Uriel N, Shah RV, Freedman JE, Moslehi J, Bick AG, Clerkin K| | PubMed
  20. Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
    Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, International ICI-Myocarditis Registry, Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE| | PubMed
  21. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
    Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, International ICI-Myocarditis Registry, Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE| | PubMed
  22. Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
    Bonaca MP, Moslehi JJ, Ledermann JA, Michelon E, Wei C, Moran M, Monk BJ, Pujade-Lauraine E| | PubMed
  23. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
    Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, Sultan D, Bredemeyer A, Bajapa G, Feng G, Jimenez J, He R, Parks A, Amrute J, Villanueva A, Liu Y, Lin CY, Mack M, Amancherla K, Moslehi J, Lavine KJ| | PubMed
  24. CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis.
    Régnier P, Le Joncour A, Maciejewski-Duval A, Darrasse-Jèze G, Dolladille C, Meijers WC, Bastarache L, Fouret P, Bruneval P, Arbaretaz F, Sayetta C, Márquez A, Rosenzwajg M, Klatzmann D, Cacoub P, Moslehi JJ, Salem JE, Saadoun D| | PubMed
  25. Immune Checkpoint Inhibitors' Effects on Calcified Aortic Plaques in Melanoma Survivors: A Retrospective Cohort Study.
    Turker I, Nair S, Terry JG, Huang S, Carr JJ, Moslehi JJ, Gupta DK, Alexander MR, Johnson DB| | PubMed
  26. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
    Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, Stein F, Bretagne M, Ederhy S, Fenioux C, Hamwy O, Funck-Brentano E, Romano E, Pieroni L, Münster JP, Allenbach Y, Anquetil C, Leonard-Louis S, Palaskas NL, Hayek SS, Katus HA, Giannitsis E, Frey N, Kaya Z, Moslehi J, Prifti E, Salem JE| | PubMed
  27. Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multicenter study.
    Amancherla K, Schlendorf KH, Vlasschaert C, Lowery BD, Wells QS, See SB, Zorn E, Colombo PC, Reilly MP, Lindenfeld J, Uriel N, Freedman JE, Shah RV, Moslehi J, Bick AG, Clerkin K| | PubMed
  28. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.
    Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, Boussouar S, Nguyen LS, Procureur A, Stein F, Fenioux C, Devos P, Gougis P, Dres M, Demoule A, Psimaras D, Lenglet T, Maisonobe T, De Chambrun MP, Hekimian G, Straus C, Gonzalez-Bermejo J, Klatzmann D, Rigolet A, Guillaume-Jugnot P, Champtiaux N, Benveniste O, Weiss N, Saheb S, Rouvier P, Plu I, Gandjbakhch E, Kerneis M, Hammoudi N, Zahr N, Llontop C, Morelot-Panzini C, Lehmann L, Qin J, Moslehi JJ, Rosenzwajg M, Similowski T, Allenbach Y| | PubMed
  29. A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma.
    Chen YC, Jaffer M, Zhou L, Moslehi J, Forsyth PA, Fecher LA| | PubMed
  30. Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
    Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, Sultan D, Bredemeyer A, Bajapa G, Feng G, Jimenez J, Parks A, Amrute J, Villanueva A, Liu Y, Lin CY, Mack M, Amancherla K, Moslehi J, Lavine KJ| | PubMed
  31. Circulating immune checkpoints predict heart failure outcomes.
    Screever EM, Yousif LIE, Moslehi JJ, Salem JE, Voors AA, Silljé HHW, de Boer RA, Meijers WC| | PubMed
  32. The next big questions in cancer research.
    Loi S, Settleman J, Joyce JA, Pramesh CS, Bernards R, Fan J, Merchant JL, Moslehi J, Sellers WR| | PubMed
  33. Diagnosis and Treatment of Acute Myocarditis: A Review.
    Ammirati E, Moslehi JJ| | PubMed
  34. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
    Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, Krug LM, Moslehi J, Pietanza MC, Riemer J, Robert C, Sharon E, Suarez-Almazor ME, Suresh K, Turner M, Weber J, Cappelli LC| | PubMed
  35. Addressing cardiovascular complications of BTK inhibitors.
    Moslehi J| | PubMed
  36. Multi-Disciplinary Management in Rectal Cancer Survivorship: A Clinical Practice Review.
    Chan H, Savoie MB, Munir A, Moslehi J, Anwar M, Laffan A, Rowen T, Salmon R, Varma M, Van Loon K| | PubMed
  37. Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions.
    Moslehi J, Salem JE| | PubMed
  38. Single-Nuclear RNA Sequencing of Endomyocardial Biopsies Identifies Persistence of Donor-Recipient Chimerism With Distinct Signatures in Severe Cardiac Allograft Vasculopathy.
    Amancherla K, Qin J, Hulke ML, Pfeiffer RD, Agrawal V, Sheng Q, Xu Y, Schlendorf KH, Lindenfeld J, Shah RV, Freedman JE, Tucker NR, Moslehi J| | PubMed
  39. T cells specific for α-myosin drive immunotherapy-related myocarditis.
    Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ, Balko JM| | PubMed
  40. Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities.
    Spetz JKE, Florido MHC, Fraser CS, Qin X, Choiniere J, Yu SJ, Singh R, Friesen M, Rubin LL, Salem JE, Moslehi JJ, Sarosiek KA| | PubMed
  41. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis.
    Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, Xi Y, Yao J, Hung MC, Calin GA, Cheng J, Lim B, Lehmann LH, Salem JE, Johnson DB, Curran MA, Yu D, Han L, Darabi R, Yang L, Moslehi JJ, Lin C| | PubMed
  42. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
    Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group| | PubMed
  43. Reply to S. Rossi et al and P. Palassin et al.
    Naqash AR, Johnson DB, Moslehi JJ, Sharon E| | PubMed
  44. A Pilot Study of Associations Between the Occurrence of Palpitations and Cytokine Gene Variations in Women Prior to Breast Cancer Surgery.
    Sheng Y, Carpenter JS, Smith BJ, Paul SM, Melisko M, Moslehi J, Levine JD, Conley YP, Kober KM, Miaskowski C| | PubMed
  45. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
    Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group| | PubMed
  46. Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma.
    Tai W, Doolittle GC, Shah Z, Atkinson JB, Russell E, Genton RE, Moslehi JJ, Porter CB| | PubMed
  47. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.
    Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, Cautela J, Francis S, Courand PY, Deswal A, Ewer SM, Aras M, Arangalage D, Ghafourian K, Fenioux C, Finke D, Peretto G, Zaha V, Itzhaki Ben Zadok O, Tajiri K, Akhter N, Levenson J, Baldassarre L, Power J, Huang S, Collet JP, Moslehi J, Salem JE, International ICI-myocarditis registry contributors| | PubMed
  48. Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism.
    Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, Nosalski R, Mikolajczyk TP, Dobosz AM, Dikalova A, Dikalov S, Streb J, Gara K, Basta P, Krolczyk J, Sulicka-Grodzicka J, Jozefczuk E, Dziewulska A, Saju B, Laksa I, Chen W, Dormer J, Tomaszewski M, Maffia P, Czesnikiewicz-Guzik M, Crea F, Dobrzyn A, Moslehi J, Grodzicki T, Harrison DG, Guzik TJ| | PubMed
  49. Reply to S. Tan et al.
    Rini BI, Moslehi JJ, Hariharan S| | PubMed
  50. Expanding the Therapeutic World of Tryptophan Metabolism.
    Wyant GA, Moslehi J| | PubMed
  51. AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease.
    Mohile S, Blaum CS, Abadir PM, Dale W, Forman DE, Fung C, Holmes HM, Moslehi J, Mustian KM, Rich MW, Whitson HE| | PubMed
  52. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
    Naqash AR, Moey MYY, Cherie Tan XW, Laharwal M, Hill V, Moka N, Finnigan S, Murray J, Johnson DB, Moslehi JJ, Sharon E| | PubMed
  53. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
    Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR| | PubMed
  54. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis.
    Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek SS, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehmann LH, Ederhy S, Moslehi J, Salem JE, International ICI-Myocarditis Registry| | PubMed
  55. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.
    Karlstaedt A, Moslehi J, de Boer RA| | PubMed
  56. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.
    Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, Pinna B, Allenbach Y, Mira JP, Moslehi J, Rosenzwajg M, Salem JE| | PubMed
  57. Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.
    Ammirati E, Bizzi E, Veronese G, Groh M, Van de Heyning CM, Lehtonen J, Pineton de Chambrun M, Cereda A, Picchi C, Trotta L, Moslehi JJ, Brucato A| | PubMed
  58. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
    Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, Motzer RJ, Atkins MB, Haanen J, Mariani M, Wang J, Hariharan S, Larkin J| | PubMed
  59. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.
    Wilcox NS, Rotz SJ, Mullen M, Song EJ, Ky Hamilton B, Moslehi J, Armenian SH, Wu JC, Rhee JW, Ky B| | PubMed
  60. 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis.
    Ederhy S, Devos P, Pinna B, Funck-Brentano E, Abbar B, Fenioux C, Cohen AA, Moslehi J, Bretagne M, Allenbach Y, Kharroubi D, Salem JE| | PubMed
  61. Immune-checkpoint inhibitors: long-term implications of toxicity.
    Johnson DB, Nebhan CA, Moslehi JJ, Balko JM| | PubMed
  62. Harnessing big data to characterize immune-related adverse events.
    Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L| | PubMed
  63. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database.
    Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, Hekimian G, Ammirati E, Ben M'Barek B, Redheuil A, Gandjbakhch E, Bihan K, Lebrun-Vignes B, Ederhy S, Dolladille C, Moslehi JJ, Salem JE| | PubMed
  64. Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association.
    Zaha VG, Hayek SS, Alexander KM, Beckie TM, Hundley WG, Kondapalli L, Ky B, Leger KJ, Meijers WC, Moslehi JJ, Shah SH| | PubMed
  65. Editorial: Recent Advances in Cardiotoxicity Testing.
    Mohamed TMA, Moslehi J, Satin J| | PubMed
  66. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
    Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, Alexandre J, Rassaf T, Müller OJ, Aras M, Asnani AH, Deswal A, Laufer-Perl M, Thuny F, Kerneis M, Hayek SS, Ederhy S, Salem JE, Moslehi JJ| | PubMed
  67. Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis.
    Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehman L, Ederhy S, Moslehi J, Salem JE, International ICI-Myocarditis Registry†| | PubMed
  68. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.
    Salem JE, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, Funck-Brentano C, Gougis P| | PubMed
  69. 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
    Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M| | PubMed
  70. PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation.
    Choudhary A, Brinkley DM, Besharati S, Meijers WC, Atkinson JB, Amancherla K, Zhu Q, Huang S, Nguyen LS, Salem JE, Ammirati E, Lindenfeld J, Anders RA, Moslehi J| | PubMed
  71. High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Hu JR, Patel A, Huang S, Su YR, Dahlman KB, Tomasek K, Zhang Y, O'Neil RT, O'Neal JF, Turker I, Johnson DB, Salem JE, Moslehi JJ, Oluwole O| | PubMed
  72. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.
    Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, Vilque JP, Plane AF, Legallois D, Champ-Rigot L, Milliez P, Funck-Brentano C, Dolladille C| | PubMed
  73. Survivorship, Version 1.2021.
    Tevaarwerk A, Denlinger CS, Sanft T, Ansbaugh SM, Armenian S, Baker KS, Broderick G, Day A, Demark-Wahnefried W, Dickinson K, Friedman DL, Ganz P, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Zee P, McMillian NR, Freedman-Cass DA| | PubMed
  74. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
    Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen LS, Alexandre J, Moslehi JJ, Dechartres A, Salem JE| | PubMed
  75. RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets.
    Amancherla K, Qin J, Wang Y, Axelrod ML, Balko JM, Schlendorf KH, Hoffman RD, Xu Y, Lindenfeld J, Moslehi J| | PubMed
  76. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
    Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ| | PubMed
  77. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ| | PubMed
  78. Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.
    Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, Ghigo A, Grumbach IM, Jain S, Zhu H, American Heart Association Council on Basic Cardiovascular Sciences; Cardio-Oncology Science Subcomm| | PubMed
  79. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
    Butler SS, Mahal BA, Moslehi JJ, Nohria A, Dee EC, Makkar R, Whitbeck A, Wangoe J, Mouw KW, Nguyen PL, Muralidhar V| | PubMed
  80. High-grade heart block associated with ibrutinib therapy.
    Vartanov AR, Lampson BL, Jacobsen ED, Alyea EP, Moslehi JJ, Brown JR| | PubMed
  81. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
    Nguyen LS, Ortuno S, Lebrun-Vignes B, Johnson DB, Moslehi JJ, Hertig A, Salem JE| | PubMed
  82. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
    Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN| | PubMed
  83. Standing at the Crossroads.
    Tang L, Moslehi J, Tang Y| | PubMed
  84. Global Longitudinal Strain in Cardio-Oncology.
    Moslehi JJ, Witteles RM| | PubMed
  85. Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation.
    Ratain MJ, Moslehi JJ, Lichter AS| | PubMed
  86. Implementation of Cardio-Oncology Training for Cardiology Fellows.
    Tuzovic M, Brown SA, Yang EH, West BH, Bassi NS, Park S, Guha A, Ghosh AK, Ganatra S, Hayek SS, Moslehi J, Jahangir E| | PubMed
  87. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors.
    Wu MD, Moslehi JJ, Lindner JR| | PubMed
  88. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
    Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, Mancuso JJ, Himmel LE, Lebrun-Vignes B, Wleklinski MJ, Knollmann BC, Srinivasan J, Li Y, Atolagbe OT, Rao X, Zhao Y, Wang J, Ehrlich LIR, Sharma P, Salem JE, Balko JM, Moslehi JJ, Allison JP| | PubMed
  89. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD, Bauersachs J, Bertero E, Coats AJS, Celutkiene J, Chioncel O, Dodion P, Eschenhagen T, Farmakis D, Bayes-Genis A, Jäger D, Jankowska EA, Kitsis RN, Konety SH, Larkin J, Lehmann L, Lenihan DJ, Maack C, Moslehi JJ, Müller OJ, Nowak-Sliwinska P, Piepoli MF, Ponikowski P, Pudil R, Rainer PP, Ruschitzka F, Sawyer D, Seferovic PM, Suter T, Thum T, van der Meer P, Van Laake LW, von Haehling S, Heymans S, Lyon AR, Backs J| | PubMed
  90. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.
    Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG, Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss HP, Tschöpe C, Cooper LT, Camici PG| | PubMed
  91. Age-Related Considerations in Cardio-Oncology.
    Screever EM, Meijers WC, Moslehi JJ| | PubMed
  92. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
    Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, Iwamoto Y, Wojtkiewicz G, Cetinbas M, Schloss MJ, Tedeschi J, Lebrun-Vignes B, Lundby A, Sadreyev RI, Moslehi J, Nahrendorf M, Ellinor PT, Milan DJ| | PubMed
  93. Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study.
    Hilmi M, Ederhy S, Waintraub X, Funck-Brentano C, Cohen A, Vozy A, Lebrun-Vignes B, Moslehi J, Nguyen LS, Salem JE| | PubMed
  94. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
    Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, Ky B, Šterba M, Cardinale D, Cohen-Solal A, Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P, Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot JS, Skouri H, Hägler-Laube ES, Asteggiano R, Fernandez TL, de Boer RA, Lyon AR| | PubMed
  95. The cancer patient and cardiology.
    Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G| | PubMed
  96. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
    Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O| | PubMed
  97. Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients: Ready for Prime Time?
    Aras MA, Power JR, Moslehi JJ| | PubMed
  98. Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.
    Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, Funck-Brentano E, Moslehi JJ, Johnson DB, Salem JE| | PubMed
  99. Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity.
    Miller JM, Meki MH, Ou Q, George SA, Gams A, Abouleisa RRE, Tang XL, Ahern BM, Giridharan GA, El-Baz A, Hill BG, Satin J, Conklin DJ, Moslehi J, Bolli R, Ribeiro AJS, Efimov IR, Mohamed TMA| | PubMed
  100. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.
    Li C, Jiang J, Wang F, Zhou N, Veronese G, Moslehi JJ, Ammirati E, Wang DW| | PubMed
  101. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
    Chen C, Wang F, Chen P, Jiang J, Cui G, Zhou N, Moroni F, Moslehi JJ, Ammirati E, Wang DW| | PubMed
  102. Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity.
    Moslehi J, Zhang Q, Moore KJ| | PubMed
  103. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
    Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, Salem JE, Wu SM, Moslehi JJ, Zhu H| | PubMed
  104. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society
    Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D| | PubMed
  105. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.
    Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, Cappelli LC, Naidoo J, Moslehi JJ| | PubMed
  106. NCCN Guidelines Insights: Survivorship, Version 2.2020.
    Denlinger CS, Sanft T, Moslehi JJ, Overholser L, Armenian S, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, O'Connor T, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Zee P, McMillian NR, Freedman-Cass DA| | PubMed
  107. Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.
    Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, Phillips EJ| | PubMed
  108. Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.
    Young AC, Quach HT, Song H, Davis EJ, Moslehi JJ, Ye F, Williams GR, Johnson DB| | PubMed
  109. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
    Patrinely JR, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB| | PubMed
  110. Tissue Is the Issue, Even During a Pandemic.
    Shah KS, Moslehi JJ, Fang JC| | PubMed
  111. Inflammation begets inflammation: cancer and acute MI.
    Kondapalli L, Moslehi J, Bonaca MP| | PubMed
  112. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
    Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B, Spano JP, Ederhy S, Klatzmann D, Rosenzwajg M, Fautrel B, Cadranel J, Johnson DB, Moslehi JJ, Salem JE| | PubMed
  113. Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis.
    Moey MYY, Gougis P, Goldschmidt V, Johnson DB, Lebrun-Vignes B, Moslehi J, Cadranel J, Salem JE| | PubMed
  114. Vascular medicine and cardio-oncology - A new, evolving clinical frontier.
    Versmissen J, Power JR, Moslehi J| | PubMed
  115. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.
    Nguyen LS, Dolladille C, Drici MD, Fenioux C, Alexandre J, Mira JP, Moslehi JJ, Roden DM, Funck-Brentano C, Salem JE| | PubMed
  116. Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective.
    Salem JE, Ederhy S, Lebrun-Vignes B, Moslehi JJ| | PubMed
  117. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
    Grouthier V, Lebrun-Vignes B, Moey M, Johnson DB, Moslehi JJ, Salem JE, Bachelot A| | PubMed
  118. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.
    Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zlotoff DA, Murphy SP, Stone JR, Golden DLA, Alvi RM, Rokicki A, Jones-O'Connor M, Cohen JV, Heinzerling LM, Mulligan C, Armanious M, Barac A, Forrestal BJ, Sullivan RJ, Kwong RY, Yang EH, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Coelho-Filho OR, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Mercurio V, Mahmoudi M, Lawrence DP, Reynolds KL, Weinsaft JW, Baksi AJ, Ederhy S, Groarke JD, Lyon AR, Fradley MG, Thavendiranathan P, Neilan TG| | PubMed
  119. COVID-19 and immune checkpoint inhibitors: initial considerations.
    Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL| | PubMed
  120. Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.
    Shah KP, Song H, Ye F, Moslehi JJ, Balko JM, Salem JE, Johnson DB| | PubMed
  121. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
    Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, Rubinstein SM, Hall R, Wyatt H, Piazza G| | PubMed
  122. Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes.
    Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, Funck-Brentano C, Glazer AM, Roden DM| | PubMed
  123. Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy.
    Ruddy KJ, Sangaralingham LR, Van Houten H, Nowsheen S, Sandhu N, Moslehi J, Neuman H, Jemal A, Haddad TC, Blaes AH, Villarraga HR, Thompson C, Shah ND, Herrmann J| | PubMed
  124. Response by Salem et al to Letter Regarding Article, "Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes".
    Salem JE, Moslehi JJ, Funck Brentano C, Roden DM| | PubMed
  125. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
    Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K, ESMO Guidelines Committee. Electronic address: [email protected]| | PubMed
  126. Solid organ transplant rejection associated with immune-checkpoint inhibitors.
    Saberianfar S, Nguyen LS, Manouchehri A, Lebrun-Vignes B, Moslehi JJ, Johnson DB, Hertig A, Salem JE| | PubMed
  127. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
    Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem JE, Beckman JA, Moslehi JJ| | PubMed
  128. Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.
    Aboumsallem JP, Moslehi J, de Boer RA| | PubMed
  129. Cardio-Immuno-Oncology.
    Zaha VG, Meijers WC, Moslehi J| | PubMed
  130. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association.
    Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Ca| | PubMed
  131. The 2019 Nobel Prize honors fundamental discoveries in hypoxia response.
    Moslehi J, Rathmell WK| | PubMed
  132. Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care.
    Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J| | PubMed
  133. Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133].
    Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF| | PubMed
  134. Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.
    Ala CK, Klein AL, Moslehi JJ| | PubMed
  135. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.
    Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ| | PubMed
  136. Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer.
    Meijers WC, Moslehi JJ| | PubMed
  137. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
    Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G| | PubMed
  138. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
    Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, Roden DM, Moslehi JJ, Salem JE| | PubMed
  139. Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
    Vozy A, De Martin E, Johnson DB, Lebrun-Vignes B, Moslehi JJ, Salem JE| | PubMed
  140. Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens.
    Cadeddu Dessalvi C, Pepe A, Penna C, Gimelli A, Madonna R, Mele D, Monte I, Novo G, Nugara C, Zito C, Moslehi JJ, de Boer RA, Lyon AR, Tocchetti CG, Mercuro G| | PubMed
  141. Cancer cachexia: getting to the heart of the matter.
    Groarke JD, Cheng S, Jones LW, Moslehi J| | PubMed
  142. Cardiovascular Toxicities Associated With Ibrutinib.
    Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ| | PubMed
  143. Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.
    Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V, Chandra A, Haykowsky M, Ky B, Moslehi J, Nohria A, Butler J, Pandey A| | PubMed
  144. Comparative Transcriptomics of Ex Vivo, Patient-Derived Endothelial Cells Reveals Novel Pathways Associated With Type 2 Diabetes Mellitus.
    Beckman JA, Doherty SP, Feldman ZB, Banks ES, Moslehi J, Jaffe IZ, Hamburg NM, Sheng Q, Brown JD| | PubMed
  145. Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes.
    Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, Funck-Brentano C, Glazer AM, Roden DM| | PubMed
  146. Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week.
    Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, Zeiher A, Jaiswal S, Schulz C, Blankstein R, Bolton KL, Steensma D, Levine RL, Ebert BL| | PubMed
  147. Fulminant Myocarditis: Evolving Diagnosis, Evolving Biology, Evolving Prognosis.
    Moslehi JJ, Brinkley DM, Meijers WC| | PubMed
  148. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.
    Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM| | PubMed
  149. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
    Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J| | PubMed
  150. NCCN Guidelines Insights: Survivorship, Version 2.2019.
    Sanft T, Denlinger CS, Armenian S, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Mooney K, Moore HCF, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Zee P, McMillian NR, Freedman-Cass DA| | PubMed
  151. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
    Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M| | PubMed
  152. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
    Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D| | PubMed
  153. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
    Stack JP, Moslehi J, Sayed N, Wu JC| | PubMed
  154. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.
    Beyer AM, Bonini MG, Moslehi J| | PubMed
  155. Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis.
    Linton MF, Moslehi JJ, Babaev VR| | PubMed
  156. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.
    Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE| | PubMed
  157. Assessing cardiac safety in oncology drug development.
    Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF| | PubMed
  158. Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need.
    Moslehi J, Fujiwara K, Guzik T| | PubMed
  159. Cardiovascular toxicities associated with immune checkpoint inhibitors.
    Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J| | PubMed
  160. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
    Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE| | PubMed
  161. Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review.
    Calvillo-Argüelles O, Jaiswal S, Shlush LI, Moslehi JJ, Schimmer A, Barac A, Thavendiranathan P| | PubMed
  162. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week.
    Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP| | PubMed
  163. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.
    Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL| | PubMed
  164. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.
    Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A| | PubMed
  165. Hematologic Complications of Immune Checkpoint Inhibitors.
    Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB| | PubMed
  166. Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.
    Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D, Harrell S, Hall R, Wyatt H, Piazza G| | PubMed
  167. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
    Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG| | PubMed
  168. The forgotten right ventricle in cardio-oncology.
    Jahangir E, Harinstein ME, Murthy VL, Moslehi J| | PubMed
  169. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
    Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, López JA, Lindner JR| | PubMed
  170. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
    Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA| | PubMed
  171. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB| | PubMed
  172. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
    Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ| | PubMed
  173. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes.
    Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC| | PubMed
  174. Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study.
    Salisbury-Ruf CT, Bertram CC, Vergeade A, Lark DS, Shi Q, Heberling ML, Fortune NL, Okoye GD, Jerome WG, Wells QS, Fessel J, Moslehi J, Chen H, Roberts LJ, Boutaud O, Gamazon ER, Zinkel SS| | PubMed
  175. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
    Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA| | PubMed
  176. Immune checkpoint inhibitors and cardiovascular toxicity.
    Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J| | PubMed
  177. Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients.
    Das S, Pineda G, Berlin J, Hemphill B, Moslehi J, Nohria A, Fisher G| | PubMed
  178. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution.
    Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y| | PubMed
  179. Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.
    Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB| | PubMed
  180. Hypogonadism as a Reversible Cause of Torsades de Pointes in Men.
    Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, Moslehi JJ, Badilini F, Haroche J, Gougis P, Fressart V, Glazer AM, Hidden-Lucet F, Touraine P, Lebrun-Vignes B, Roden DM, Bachelot A, Funck-Brentano C| | PubMed
  181. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention.
    Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, van der Pal HJ, van Dalen EC, Kremer LCM| | PubMed
  182. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.
    Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA, Lindenfeld J, Murphy MJ, Moslehi JJ, Checkpoint Inhibitor Safety Working Group| | PubMed
  183. Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers.
    Blaes AH, Thavendiranathan P, Moslehi J| | PubMed
  184. In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.
    Cai C, Fang J, Guo P, Wang Q, Hong H, Moslehi J, Cheng F| | PubMed
  185. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
    Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, Courtillot C, Bachelot A, Roden DM, Moslehi JJ, Salem JE| | PubMed
  186. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms.
    Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE| | PubMed
  187. Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase.
    McBrayer SK, Olenchock BA, DiNatale GJ, Shi DD, Khanal J, Jennings RB, Novak JS, Oser MG, Robbins AK, Modiste R, Bonal D, Moslehi J, Bronson RT, Neuberg D, Nguyen QD, Signoretti S, Losman JA, Kaelin WG| | PubMed
  188. Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic.
    Yang T, Meoli DF, Moslehi J, Roden DM| | PubMed
  189. Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment.
    Spetz J, Moslehi J, Sarosiek K| | PubMed
  190. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
    Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG| | PubMed
  191. Comorbidities: Cardiovascular disease and breast cancer.
    Moey M, Moslehi J| | PubMed
  192. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
    Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB| | PubMed
  193. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.
    Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J| | PubMed
  194. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
    Barber MC, Mauro MJ, Moslehi J| | PubMed
  195. The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.
    Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR| | PubMed
  196. Smoldering myocarditis following immune checkpoint blockade.
    Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM| | PubMed
  197. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
    Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J| | PubMed
  198. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR| | PubMed
  199. Loss of the melanocortin-4 receptor in mice causes dilated cardiomyopathy.
    Litt MJ, Okoye GD, Lark D, Cakir I, Moore C, Barber MC, Atkinson J, Fessel J, Moslehi J, Cone RD| | PubMed
  200. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
    Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA| | PubMed
  201. Grounding Cardio-Oncology in Basic and Clinical Science.
    Moslehi J, Amgalan D, Kitsis RN| | PubMed
  202. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
    Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J| | PubMed
  203. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
    Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM| | PubMed
  204. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
    Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG| | PubMed
  205. Cardio-Oncology: Vascular Endothelial Growth Factor Inhibitors, Salt, and Macrophages: A Complicated Interaction.
    Moslehi J, Pandey AK, Bhatia N| | PubMed
  206. Cardiovascular Toxicities Associated with Cancer Immunotherapies.
    Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ| | PubMed
  207. Cardio-Oncology: Time to Get More Mechanistic.
    Moslehi J, Lenihan DJ| | PubMed
  208. Ventricular arrhythmias and sudden death in patients taking ibrutinib.
    Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR| | PubMed
  209. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC| | PubMed
  210. Myocarditis with Immune Checkpoint Blockade.
    Moslehi JJ, Johnson DB, Sosman JA| | PubMed
  211. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.
    Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A| | PubMed
  212. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
    Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D| | PubMed
  213. Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
    Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ| | PubMed
  214. Cardiovascular Toxic Effects of Targeted Cancer Therapies.
    Moslehi JJ| | PubMed
  215. 21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.
    Sheng CC, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, Croce K, Kim G, Moslehi J| | PubMed
  216. NCCN Guidelines Insights: Survivorship, Version 1.2016.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Sanft T, Silverman P, Smith S, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA| | PubMed
  217. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.
    Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH| | PubMed
  218. EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.
    Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG| | PubMed
  219. Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty.
    Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J| | PubMed
  220. Cardiovascular Complications of Novel Multiple Myeloma Treatments.
    Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J| | PubMed
  221. EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.
    Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG| | PubMed
  222. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.
    Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J| | PubMed
  223. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM| | PubMed
  224. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
    Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ| | PubMed
  225. Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training.
    Scott JM, Armenian S, Giralt S, Moslehi J, Wang T, Jones LW| | PubMed
  226. Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis.
    Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J| | PubMed
  227. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
    Moslehi JJ, Deininger M| | PubMed
  228. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.
    Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J| | PubMed
  229. QT Prolongation and Oncology Drug Development.
    Fradley MG, Moslehi J| | PubMed
  230. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes.
    Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, Forman DE, Di Carli MF, Nohria A| | PubMed
  231. Survivorship: screening for cancer and treatment effects, version 2.2014.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA| | PubMed
  232. ABCDE steps to prevent heart disease in breast cancer survivors.
    Montazeri K, Unitt C, Foody JM, Harris JR, Partridge AH, Moslehi J| | PubMed
  233. Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National Comprehensive Cancer Network| | PubMed
  234. Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary.
    Koelwyn GJ, Jones LW, Moslehi J| | PubMed
  235. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
    Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J| | PubMed
  236. Survivorship: healthy lifestyles, version 2.2014.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National comprehensive cancer network| | PubMed
  237. Survivorship: immunizations and prevention of infections, version 2.2014.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA| | PubMed
  238. The challenge of cross-trial comparisons using limited data.
    Laubach JP, Faber EA, Voorhees P, Moslehi J, Varga C, Niculescu L, Anderson KC, Richardson PG| | PubMed
  239. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.
    Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, Gygi SP, Kaelin WG, Zhang Q| | PubMed
  240. Survivorship: cognitive function, version 1.2014.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National Comprehensive Cancer Network| | PubMed
  241. Cardiology patient page. Breast cancer chemotherapy and your heart.
    Unitt C, Montazeri K, Tolaney S, Moslehi J| | PubMed
  242. Survivorship: fatigue, version 1.2014.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D| | PubMed
  243. Survivorship: sleep disorders, version 1.2014.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D, National Comprehensive Cancer Network| | PubMed
  244. Survivorship: pain version 1.2014.
    Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D, National Comprehensive Cancer Network| | PubMed
  245. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
    Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK| | PubMed
  246. Heart failure and breast cancer therapies: moving towards personalized risk assessment.
    Francis SA, Cheng S, Arteaga CL, Moslehi J| | PubMed
  247. Real-time three-dimensional transoesophageal echocardiography enables preoperative pulmonary valvulopathy assessment.
    Waller AH, Chatzizisis YS, Moslehi JJ, Chen FY, Mangion JR| | PubMed
  248. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging.
    Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA| | PubMed
  249. Cancer-drug discovery and cardiovascular surveillance.
    Groarke JD, Cheng S, Moslehi J| | PubMed
  250. A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease.
    Liu D, Wang CJ, Judge DP, Halushka MK, Ni J, Habashi JP, Moslehi J, Bedja D, Gabrielson KL, Xu H, Qian F, Huso D, Dietz HC, Germino GG, Watnick T| | PubMed
  251. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling.
    Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, Marchini JF, Schissler A, Padera RF, Shi J, Cheng HW, Raghuram S, Arany Z, Liao R, Croce K, MacRae C, Feinberg MW| | PubMed
  252. Emerging paradigms in cardiomyopathies associated with cancer therapies.
    Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ| | PubMed
  253. Cardio-oncology: it takes two to translate.
    Moslehi J, Cheng S| | PubMed
  254. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease.
    Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J| | PubMed
  255. The cardiovascular perils of cancer survivorship.
    Moslehi J| | PubMed
  256. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
    Bair SM, Choueiri TK, Moslehi J| | PubMed
  257. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
    Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M| | PubMed
  258. Breast cancer therapies and cardiomyopathy.
    Groarke J, Tong D, Khambhati J, Cheng S, Moslehi J| | PubMed
  259. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.
    Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, Moslehi J, Kwong RY| | PubMed
  260. Management of antiangiogenic therapy-induced hypertension.
    de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD| | PubMed
  261. Treatment of erythropoietin deficiency in mice with systemically administered siRNA.
    Querbes W, Bogorad RL, Moslehi J, Wong J, Chan AY, Bulgakova E, Kuchimanchi S, Akinc A, Fitzgerald K, Koteliansky V, Kaelin WG| | PubMed
  262. Telomeres and mitochondria in the aging heart.
    Moslehi J, DePinho RA, Sahin E| | PubMed
  263. You can't run from inflammation: lower extremity ischemia, hypoxia signaling, and macrophage subtypes.
    Moslehi J, Libby P| | PubMed
  264. Reversible cardiomyopathy associated with sunitinib and sorafenib.
    Uraizee I, Cheng S, Moslehi J| | PubMed
  265. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.
    Nazer B, Humphreys BD, Moslehi J| | PubMed
  266. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
    Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK| | PubMed
  267. Telomere dysfunction induces metabolic and mitochondrial compromise.
    Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA| | PubMed
  268. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.
    Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG| | PubMed
  269. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo.
    Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG| | PubMed
  270. Paragangliomas: etiology, presentation, and management.
    Joynt KE, Moslehi JJ, Baughman KL| | PubMed
  271. Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature.
    Sung AD, Cheng S, Moslehi J, Scully EP, Prior JM, Loscalzo J| | PubMed
  272. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure.
    Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG| | PubMed
  273. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
    Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA| | PubMed
  274. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ| | PubMed
  275. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells.
    Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, Kaelin WG| | PubMed
  276. Posterior urethral valves presented at birth despite normal prenatal ultrasound scans.
    Moslehi J, Herndon CD, McKenna PH| | PubMed
  277. Nucleated conformational conversion and the replication of conformational information by a prion determinant.
    Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, Arnsdorf MF, Lindquist SL| | PubMed
  278. Yeast prion [psi +] and its determinant, Sup35p.
    Serio TR, Cashikar AG, Moslehi JJ, Kowal AS, Lindquist SL| | PubMed
  279. Influence of antigen organization on the development of lupus autoantibodies.
    Fatenejad S, Bennett M, Moslehi J, Craft J| | PubMed
  280. Perforin protects against autoimmunity in lupus-prone mice.
    Peng SL, Moslehi J, Robert ME, Craft J| | PubMed
  281. Roles of interferon-gamma and interleukin-4 in murine lupus.
    Peng SL, Moslehi J, Craft J| | PubMed